 HOUSTON, April 27, 2021 PRNewswire -- Marker Therapeutics, Inc. Nasdaq:MRKR, a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it will present data detailing a new robotics technology to aid in multi-tumor-associated antigen mTAA-specific T cell therapy manufacturing at the upcoming American Society of Gene Cell Therapy ASGCT Annual Meeting, taking place virtually May 11-14, 2021. The data will be presented by lead author Anastasiya Smith, Ph.D. 